We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Novel biomarkers in bladder cancer.
Urologic Oncology 2018 March
A sea change has occurred in the treatment options available for metastatic urothelial bladder cancer with the recent Food and Drug Administration approval of 5 immune checkpoint blockade agents for patients who have progressed on platinum-based chemotherapy or are not candidates for cisplatin. Additionally, comprehensive characterization of the landscape of genomic alterations in this disease through The Cancer Genome Atlas and other efforts has detected numerous potential targets for small molecule inhibitors. Detailed analysis of the urothelial carcinoma transcriptome has allowed for molecular subtyping of the disease and the ramifications of these subtypes upon treatment response is an active area of investigation. Coupled with these advances is a critical unmet need to define predictive biomarkers of response to therapy. Here, we highlight select research relevant to the validation and continued discovery of novel biomarkers to advance precision oncology in bladder cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app